NewLink Genetics (NLNK) Given a $26.00 Price Target at Cantor Fitzgerald

Cantor Fitzgerald set a $26.00 target price on NewLink Genetics (NASDAQ:NLNK) in a report published on Friday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other research firms have also recently weighed in on NLNK. BidaskClub upgraded shares of NewLink Genetics from a sell rating to a hold rating in a research report on Friday, January 5th. Zacks Investment Research cut shares of NewLink Genetics from a buy rating to a hold rating in a research report on Thursday, January 4th. Bank of America decreased their price objective on shares of NewLink Genetics from $22.00 to $18.00 and set a buy rating on the stock in a research report on Friday, March 2nd. Finally, Stifel Nicolaus restated a buy rating and issued a $21.00 price objective (down from $25.00) on shares of NewLink Genetics in a research report on Friday, March 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $20.17.

How to Become a New Pot Stock Millionaire

Shares of NewLink Genetics stock traded down $3.12 on Friday, reaching $4.20. The stock had a trading volume of 15,289,220 shares, compared to its average volume of 666,886. NewLink Genetics has a 1 year low of $3.95 and a 1 year high of $20.47. The company has a market cap of $271.98, a price-to-earnings ratio of -1.83 and a beta of 1.22.

NewLink Genetics (NASDAQ:NLNK) last posted its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.32. The company had revenue of $10.10 million for the quarter, compared to analysts’ expectations of $2.72 million. NewLink Genetics had a negative net margin of 250.60% and a negative return on equity of 60.60%. equities research analysts expect that NewLink Genetics will post -2.35 EPS for the current year.

Several hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank grew its position in NewLink Genetics by 1,823.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,269 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 9,735 shares during the last quarter. Raymond James Financial Services Advisors Inc. bought a new position in NewLink Genetics during the fourth quarter valued at approximately $118,000. The Manufacturers Life Insurance Company grew its position in NewLink Genetics by 3.0% during the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock valued at $140,000 after acquiring an additional 556 shares during the last quarter. Creative Planning bought a new position in NewLink Genetics during the fourth quarter valued at approximately $152,000. Finally, Acadian Asset Management LLC grew its position in NewLink Genetics by 241.6% during the fourth quarter. Acadian Asset Management LLC now owns 19,470 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 13,770 shares during the last quarter. Institutional investors own 65.05% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “NewLink Genetics (NLNK) Given a $26.00 Price Target at Cantor Fitzgerald” was reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3338490/newlink-genetics-nlnk-given-a-26-00-price-target-at-cantor-fitzgerald.html.

About NewLink Genetics

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Aaron’s   Shares Down 6.2%  on Disappointing Earnings
Aaron’s Shares Down 6.2% on Disappointing Earnings
Box  Expected to Announce Quarterly Sales of $139.55 Million
Box Expected to Announce Quarterly Sales of $139.55 Million
Statoil  Shares Gap Up  Following Dividend Announcement
Statoil Shares Gap Up Following Dividend Announcement
Meritage Homes  Trading Up 0% After Strong Earnings
Meritage Homes Trading Up 0% After Strong Earnings
Eldorado Gold Corp  Announces Quarterly Dividend of $0.50
Eldorado Gold Corp Announces Quarterly Dividend of $0.50
Sunoco LP Announces Quarterly Dividend of $0.83
Sunoco LP Announces Quarterly Dividend of $0.83


© 2006-2018 Ticker Report. Google+.